BTIG Maintains Buy Rating on Insulet (PODD)

On April 13, 2026, BTIG lowered the terms people connected Insulet Corporation (NASDAQ:PODD) to $320 from $380 and maintained a Buy standing arsenic portion of a broader aesculapian exertion update. BTIG said it adjusted its exemplary pursuing CMS’ projected FY27 inpatient prospective outgo strategy rule, which includes commentary and decisions connected caller exertion add-on payments.

On April 7, 2026, Citi downgraded Insulet Corporation (NASDAQ:PODD) to Neutral from Buy with a terms people of $230, down from $338, up of the Q1 report. Citi cited expanding contention successful the spot pump market, noting that caller merchandise launches successful 2027 could bounds stock outperformance.

Meanwhile, connected April 6, 2026, Evercore ISI lowered its terms people connected Insulet Corporation (NASDAQ:PODD) to $240 from $340 antecedently and maintained an Outperform standing arsenic portion of its Q1 preview for aesculapian exertion and beingness subject tools.

Insulet Corporation (NASDAQ:PODD) develops and sells insulin transportation systems for diabetes patients.

While we admit the imaginable of PODD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.